AltruBio

Differentiated & Niche Product Pipeline

• Product Candidate
  Indication

  • Preclinical
  • Phase I
  • Phase IIa
  • Phase IIb
  • Phase lll
  • Market
• Immunology Product - PSGL-1: T-cell Checkpoint Regulator Platform

• AbGn-168H Neihulizumab

  Psoriatic Arthritis

  • Preclinical

  • Phase I

  • Phase IIa

  • Phase IIb

  • Phase lll

  • Market

  • Phase II

  Phase 2a Psoriatic Arthritis trial completed with proof of clinical efficacy achieved.

  Ulcerative Colitis

  • Preclinical

  • Phase I

  • Phase IIa

  • Phase IIb

  • Phase lll

  • Market

  • Phase II

  Phase 2a anti-TNF α and/or anti-integrin refractory/intolerant Ulcerative Colitis trial completed with proof of clinical efficacy achieved; continued UC development planned with leiolizumab.

  Steroid Refractory Acute Graft Versus Host Disease

  • Preclinical

  • Phase I

  • Phase IIa

  • Phase IIb

  • Phase lll

  • Market

  • Phase I

  Phase 1b multi-dose steroid refractory acute graft versus host disease trial ongoing

  Acute Graft Versus Host Disease

  • Preclinical

  • Phase I

  • Phase IIa

  • Phase IIb

  • Phase lll

  • Market

  • Phase I

  Investigator sponsored Phase 1 front line acute graft versus host disease trial ongoing.

  Solid Organ Transplantation

  • Preclinical

  • Phase I

  • Phase IIa

  • Phase IIb

  • Phase lll

  • Market

  • Phase I

  Renal Transplantation Non-Human Primate preclinical studies ongoing.

  more

• AbGn-268 Leiolizumab

  Inflammation Disease

  • Preclinical

  • Phase I

  • Phase IIa

  • Phase IIb

  • Phase lll

  • Market

  • Preclinical

  Potency improved version of AbGn-168H for Chronic Inflammatory Disease

  more

• Product Candidate
  Indication

  • Preclinical
  • Phase I
  • Phase IIa
  • Phase IIb
  • Phase lll
  • Market

Mar, 2020